<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03979638</url>
  </required_header>
  <id_info>
    <org_study_id>BUS-P2-01</org_study_id>
    <secondary_id>2019-000375-16</secondary_id>
    <nct_id>NCT03979638</nct_id>
  </id_info>
  <brief_title>A Dose Escalation Study of BLU-5937 in Unexplained or Refractory Chronic Cough</brief_title>
  <acronym>RELIEF</acronym>
  <official_title>A Randomized, Double-Blind, Placebo-Controlled, Crossover, Dose Escalation Study of BLU-5937 in Subjects With Unexplained or Refractory Chronic Cough (RELIEF)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Bellus Health Inc</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Bellus Health Inc</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a multi-center, randomized, double-blind, placebo-controlled, crossover, dose
      escalation study of BLU-5937 in subjects with unexplained or refractory chronic cough
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study will have two 16-day treatment periods (four escalating doses or matching placebo
      at four days interval) separated by a 10 to 14-day washout period. There will be a 14-day
      follow-up period.
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Trial was terminated due to the impact of the COVID-19 on trial activities. 68 patients with
    refractory chronic cough were enrolled with 52 completing treatment
  </why_stopped>
  <start_date type="Actual">July 10, 2019</start_date>
  <completion_date type="Actual">April 20, 2020</completion_date>
  <primary_completion_date type="Actual">April 20, 2020</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <intervention_model_description>Two-arm, Two-Period, crossover assignment</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Awake coughs per hour at Days 4, 8, 12, 16, 34, 38, 42, 46</measure>
    <time_frame>Change from Baseline at Days 4, 8, 12, 16, 34, 38, 42, 46</time_frame>
    <description>Assessment of awake coughs per hour (average hourly cough frequency while the subject is awake based on sound recordings) evaluated using the VitaloJAK cough monitor</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>24-hour coughs per hour at Days 4, 8, 12, 16, 34, 38, 42, 46</measure>
    <time_frame>Change from Baseline at Days 4, 8, 12, 16, 34, 38, 42, 46</time_frame>
    <description>Assessment of awake coughs per hour (average hourly cough frequency based on 24-hour sound recordings) evaluated using the VitaloJAK cough monitor</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of subjects who have at least one adverse event (AE) during the two treatment periods, washout, and follow-up</measure>
    <time_frame>Time Frame: up to 60 days</time_frame>
    <description>Assessment of subjects who have at least one AE during treatment period 1 (16 days), during washout (14 days), during treatment period 2 (16 days), and follow-up (14 days)</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">68</enrollment>
  <condition>Chronic Refractory Cough</condition>
  <arm_group>
    <arm_group_label>BLU-5937 oral tablet BID</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Randomized crossover design of 4 different doses (25, 50, 100, 200 mg BID) of BLU-5937 tablets to be administered orally BID</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo oral tablet BID</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Randomized crossover design of matching placebo tablets to be administered orally BID</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BLU-5937</intervention_name>
    <description>Four escalating doses of BLU-5937 administered BID over the course of the study</description>
    <arm_group_label>BLU-5937 oral tablet BID</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Matching placebo for BLU-5937</description>
    <arm_group_label>Placebo oral tablet BID</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Unexplained or refractory chronic cough for at least one year

          -  Chest radiograph or CT thorax within the last 60 months not demonstrating any
             abnormality considered to be significantly contributing to the chronic cough

          -  Cough count of ≥ 10 per hour (Awake Cough Count) at Screening

          -  Score of ≥ 40mm on the Cough Severity VAS at Screening

          -  Women of child-bearing potential must have a negative serum pregnancy test at
             Screening

          -  Women of child-bearing potential must use a highly effective contraception method from
             Screening through the Follow-Up Visit

          -  Male subjects and their partners of child-bearing potential must use 2 methods of
             acceptable birth control

        Exclusion Criteria:

          -  Current smoker or individuals who have given up smoking within the past 6 months, or
             those with &gt;20 pack-year smoking history

          -  Diagnosis of COPD, bronchiectasis, idiopathic pulmonary fibrosis

          -  Treatment with an ACE-inhibitor as the potential cause of a subject's cough, or
             requiring treatment with an ACE-inhibitor during the study, or within 12 weeks prior
             to the Screening Visit

          -  FEV1/FVC &lt; 60%

          -  History of upper respiratory tract infection or recent significant change in pulmonary
             status within 4 weeks of the Baseline Visit

          -  History of concurrent malignancy or recurrence of malignancy within 2 years prior to
             Screening

          -  History of a diagnosis of drug or alcohol dependency or abuse within the last 3 years

          -  Clinically significant abnormal electrocardiogram (ECG) or laboratory tests at
             Screening

          -  Other severe, acute, or chronic medical or psychiatric condition or laboratory
             abnormality that may increase the risk associated with trial participation or
             investigational product administration or may interfere with the interpretation of
             trial results
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jacky Smith, MD, Ph.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Manchester</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Allergy Associates Medical Group Inc.</name>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <zip>92108</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Allergy &amp; Asthma Associates of Santa Clara Valley</name>
      <address>
        <city>San Jose</city>
        <state>California</state>
        <zip>95117</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre for Cough</name>
      <address>
        <city>Largo</city>
        <state>Florida</state>
        <zip>33778</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Research Institute</name>
      <address>
        <city>Minneapolis</city>
        <state>Minnesota</state>
        <zip>55402</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Research of Gastonia</name>
      <address>
        <city>Gastonia</city>
        <state>North Carolina</state>
        <zip>20854</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>National Allergy &amp; Asthma Research</name>
      <address>
        <city>Charleston</city>
        <state>South Carolina</state>
        <zip>29420</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Diagnostics Research Group</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78229</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Allergy Asthma &amp; Sinus Center</name>
      <address>
        <city>Greenfield</city>
        <state>Wisconsin</state>
        <zip>53228</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Belfast City Hospital</name>
      <address>
        <city>Belfast</city>
        <zip>BT9 7BL</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Castle Hill Hospital</name>
      <address>
        <city>Cottingham</city>
        <zip>HU16 5JQ</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Hospitals of Leicester</name>
      <address>
        <city>Leicester</city>
        <zip>LE3 9QP</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Prince Phillip Hospital</name>
      <address>
        <city>Llanelli</city>
        <zip>SA14 8QF</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>King's College Hospital</name>
      <address>
        <city>London</city>
        <zip>SE5 9RS</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Royal Brompton Hospital</name>
      <address>
        <city>London</city>
        <zip>SW3 6HP</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Manchester Clinical Research Facility</name>
      <address>
        <city>Manchester</city>
        <zip>M23 9LT</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>North Tyneside General Hospital</name>
      <address>
        <city>North Shields</city>
        <zip>NE29 8NH</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United Kingdom</country>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2020</verification_date>
  <study_first_submitted>June 6, 2019</study_first_submitted>
  <study_first_submitted_qc>June 6, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">June 7, 2019</study_first_posted>
  <last_update_submitted>April 27, 2020</last_update_submitted>
  <last_update_submitted_qc>April 27, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">April 29, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Unexplained or refractory chronic cough, P2X3 antagonists</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cough</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

